CTAD 2023: Subcutaneous Leqembi Bests I.V., Could Open Access

At-Home Option An Important Growth Driver for Eisai/Biogen

 
• By Mandy Jackson
Alzheimer's disease, Amyloid plaques aggregates, 3d illustration
Amyloid plaque clearance was 14% greater with subcutaneous Leqembi • Source: Shutterstock

More from Clinical Trials

More from R&D